Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 208

The DOI matches its Crossref record.

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

Schrag, Deborah, Garewal, Harinder S., Burstein, Harold J., Samson, David J., Von Hoff, Daniel D., Somerfield, Mark R. · 2004 · Journal of Clinical Oncology

Abstract

Purpose: To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to define the role of these tests in routine oncology practice. Methods: The American Society of Clinical Oncology (ASCO) established a Working Group to develop the technology assessment. The Working Group collaborated with the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center. The Working Group developed independent criteria for selecting articles for inclusion in the ASCO assessment, and developed a structured data abstraction tool to facilitate review of selected manuscripts. One Working Group member and an ASCO staff member independently reviewed the 1,139 abstracts identified by the BCBSA comprehensive literature search, and by an updated literature search performed by ASCO using the BCBSA search strategy (1966 to January 2004). Of the 12 articles included in this technology assessment, eight were identified by the original BCBSA systematic review, one was provided by industry, and three were identified by the ASCO updated literature review. Results: Review of the literature does not identify any CSRAs for which the evidence base is sufficient to support use in oncology practice. Recommendations: The use of chemotherapy sensitivity and resistance assays to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting. Oncologists should make chemotherapy treatment recommendations on the basis of published reports of clinical trials and a patient's health status and treatment preferences. Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.05.065

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 208

Metadata

Authors
Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Von Hoff, D. D., & Somerfield, M. R.
Venue
Journal of Clinical Oncology
Published
2004-09-01
Volume
22
Issue
17
Pages
3631-3638
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2136644329
Cited by
208
References
0
FWCI
6.37
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays. https://app.cochat.ai/papers/10.1200/jco.2004.05.065
The paper
Schrag, D., Garewal, H. S., Burstein, H. J., Samson, D. J., Von Hoff, D. D., & Somerfield, M. R. (2004). American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.05.065

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.